Aspen – AZ portfolio
June 10, 2016
Aspen Holdings has announced
that its wholly owned subsidiary
Aspen Global Incorporated (AGI),
has signed an agreement with
AstraZeneca AB and AstraZeneca
UK (AZ) whereby AGI will
acquire the exclusive rights
to commercialise AZ’s global
anaesthetics portfolio, with the
exception of the US business.
AZ’s anaesthetics portfolio
comprises seven established
medicines, namely Diprivan
(general anaesthesia), EMLA
(topical anaesthetic) and five local
anaesthetics (Xylocaine/Xylocard/
Xyloproct, Marcaine, Naropin,
Carbocaine and Citanest).
The products are sold in more
than one hundred countries
worldwide including China, Japan,
Australia and Brazil, generating
revenue of US$592m in the year
ended 31 Dec 2015.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jun 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jun 16
